A Model of Fatal Acute Lung Injury and Acute Respiratory Distress Syndrome
https://doi.org/10.33647/2074-5982-16-4-24-33
Abstract
This study was aimed at developing an experimental model of fatal acute lung injury and acute respiratory distress syndrome (ARDS) based on the intratracheal administration of bacterial lipopolysaccharide (LPS) in combination with muramylpeptide and Freund’s complete adjuvant to C57Bl/6Y mice sensitized with α-galactosylceramide. The developed model is characterized by diffuse alveolar damage to the lungs and high mortality rates, as well as by a multifold increase in the mRNA level of interleukin-6 in the lungs. The model can be used for assessing the efficacy of drug candidates in the treatment of acute lung injury and ARDS, including in COVID-19.
About the Authors
I. A. Pomytkin
Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Igor A. Pomytkin, Cand. Sci. (Chem.)
143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1
V. N. Karkischenko
Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Vladislav N. Karkischenko, Dr. Sci. (Med.), Prof.
143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1
Yu. V. Fokin
Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Yuriy V. Fokin, Cand. Sci. (Biol.)
143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1
M. S. Nesterov
Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Maxim S. Nesterov
143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1
N. V. Petrova
Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Nataliya V. Petrova
143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1
References
1. Karkischenko N.N. Al’ternativy biomediciny. T. 1. Osnovy biomediciny i farmakomodelirovaniya [Biomedicine alternatives. Vol. 1. Fundamentals of biomedicine and pharmaco-modeling]. Moscow: Izdatel’stvo VPK, 2007. 320 p. (In Russian).
2. Karkischenko N.N. Osnovy biomodelirovaniya [Basics of biomodeling]. Moscow: Mezhakademicheskoye Izdatel’stvo VPK, 2004. 607 p. (In Russian).
3. Rukovodstvo po laboratornym zhivotnym i al’ternativnym modelyam v biomedicinskih issledovaniyah [Manual on laboratory animals and alternative models in biomedical research]. Ed. by N.N. Karkischenko, et al. Moscow: Profil’-2S Publ., 2010. 358 p. (In Russian).
4. Aoyagi T., Yamamoto N., Hatta M., Tanno D., Miyazato A., Ishii K., et al. Activation of pulmonary invariant NKT cells leads to exacerbation of acute lung injury caused by LPS through local production of IFN-γ and TNF-α by Gr-1+ monocytes. Int. Immunol. 2011;23(2):97–108.
5. Bacci M.R., Leme R.C., Zing N.P., Murad N., Adami F., Hinnig P.F., et al. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med. Biol. Res. 2015;48(5):427–432.
6. Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P., et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(10):1065–1072.
7. Crosby C.M., Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat. Rev. Immunol. 2018;18(9):559–574.
8. D’Alessio F.R. Mouse Models of Acute Lung Injury and ARDS. Methods Mol. Biol. 2018;1809:341–350.
9. Davey R.T. Jr., Lynfield R., Dwyer D.E., Losso M.H., Cozzi-Lepri A., Wentworth D., et al. INSIGHT FLU 002 & 003 Study Groups. The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One. 2013;8(2):e57121.
10. Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13–24.
11. Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020;58(7):1021–1028.
12. Kudo D., Toyama M., Aoyagi T., Akahori Y., Yamamoto H., Ishii K., et al. Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome. Clin. Exp. Immunol. 2013;173(2):276–287.
13. Liu T., Zhang L., Joo D., Sun S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017;2. DOI: 10.1038/sigtrans.2017.23.
14. McGonagle D., Sharif K., O’Regan A., Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020;19(6):102537.
15. Ogawa C., Liu Y.J., Kobayashi K.S. Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr. Bioact. Compd. 2011;7(3):180–197.
16. Potey P.M., Rossi A.G., Lucas C.D., Dorward D.A. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential. J. Pathol. 2019;247(5):672–685.
17. Rincon M., Irvin C.G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int. J. Biol. Sci. 2012;8(9):1281–1290.
18. Zhao J., Li X., Gao Y., Huang W. Risk factors for the exacerbation of patients with 2019 Novel Coronavirus: A meta-analysis. Int. J. Med. Sci. 2020;17(12):17441750.
Review
For citations:
Pomytkin I.A., Karkischenko V.N., Fokin Yu.V., Nesterov M.S., Petrova N.V. A Model of Fatal Acute Lung Injury and Acute Respiratory Distress Syndrome. Journal Biomed. 2020;16(4):24-33. (In Russ.) https://doi.org/10.33647/2074-5982-16-4-24-33
Views:
924
Email this article 
